Syndax Pharmaceuticals will have a first-mover advantage as it launches Revuforj (revumenib) for relapsed/refractory acute leukemias in adult and pediatric patients with KMT2A translocations, following the drug’s US Food and Drug Administration approval.
The FDA approved Revuforj on 15 November as the first menin inhibitor, for patients aged 1 and older with acute...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?